Dextran sulfate-low molecular weight - TikoMed

Drug Profile

Dextran sulfate-low molecular weight - TikoMed

Alternative Names: Dextran sulfate sodium; DSSS5; IBsolvMIR; Low molecular weight dextran sulfate; TM-400

Latest Information Update: 26 Sep 2016

Price : $50

At a glance

  • Originator TikoMed
  • Developer TikoMed; Uppsala University
  • Class Anticoagulants; Antihyperlipidaemics; Glucans; Small molecules
  • Mechanism of Action Blood coagulation factor inhibitors; Complement system protein inhibitors; Immunosuppressants; Intracellular signalling peptide and protein stimulants; Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation; Pancreas transplant rejection
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Pancreas transplant rejection

Highest Development Phases

  • Phase II Pancreas transplant rejection
  • Phase I Haematological malignancies

Most Recent Events

  • 26 Sep 2016 Phase-II development for Pancreas transplant rejection is ongoing in Sweden
  • 21 Aug 2014 Tikomed completes a phase II trial in Pancreas transplant rejection (Combination therapy) in Sweden (EudraCT2008-001210-25 )
  • 21 May 2014 Phase-I clinical trials in Haematological malignancies (Combination therapy, In healthy volunteers) in Sweden (IV) (EudraCT2014-000659-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top